Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
P3H2 antisense RNA 1 (P3H2-AS1), also known as LEPREL1-AS1, is a long non-coding antisense RNA gene located on chromosome 3 that is transcribed from the strand opposite to the protein-coding LEPREL1 gene[3][5][9]. As an antisense RNA, it is classified as a long non-coding RNA (lncRNA) and is thought to potentially regulate the expression of the LEPREL1 gene by mechanisms such as transcriptional interference or RNA-induced translation inhibition[2][10]. LEPREL1 encodes prolyl 3-hydroxylase 2, an enzyme essential for collagen modification and normal eye development, and loss-of-function mutations in LEPREL1 can cause severe ocular disorders[1][8]; however, there is currently no direct evidence that P3H2-AS1 itself is a therapeutic target, disease gene, or biomarker[2][3][7][9]. No drugs targeting P3H2-AS1 or disease links specific to this RNA have been reported, and its biological function remains largely uncharacterized.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on P3H2 antisense RNA 1 (P3H2-AS1).